Nicolau D - Search Results

1

Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.

Kuti JL, Nightingale CH, Quintiliani R, Nicolau D. Kuti JL, et al. Among authors: nicolau d. Diagn Microbiol Infect Dis. 2002 Sep;44(1):51-7. doi: 10.1016/s0732-8893(02)00416-9. Diagn Microbiol Infect Dis. 2002. PMID: 12376031

2

Containing costs and containing bugs: are they mutually exclusive?

Nicolau DP. Nicolau DP. J Manag Care Pharm. 2009 Mar;15(2 Suppl):S12-7. doi: 10.18553/jmcp.2009.15.s2.12. J Manag Care Pharm. 2009. PMID: 19236136 Free PMC article.

3

Optimizing skin and skin structure infection outcomes: considerations of cost of care.

Almarzoky Abuhussain SS, Goodlet KJ, Nailor MD, Nicolau DP. Almarzoky Abuhussain SS, et al. Among authors: nicolau dp. Expert Rev Pharmacoecon Outcomes Res. 2018 Jun;18(3):235-244. doi: 10.1080/14737167.2018.1450142. Epub 2018 Mar 14. Expert Rev Pharmacoecon Outcomes Res. 2018. PMID: 29521147 Review.

4

The costs of burn care: an analysis with an emphasis on the use of parenteral antimicrobials.

Nicolau DP, White RL, Friedrich LV, Kays MB. Nicolau DP, et al. J Burn Care Rehabil. 1994 May-Jun;15(3):244-50. doi: 10.1097/00004630-199405000-00008. J Burn Care Rehabil. 1994. PMID: 8056815

5

Tetracycline-induced pancreatitis.

Nicolau DP, Mengedoht DE, Kline JJ. Nicolau DP, et al. Am J Gastroenterol. 1991 Nov;86(11):1669-71. Am J Gastroenterol. 1991. PMID: 1951248 Review.

6

Pharmacokinetic/pharmacodynamic analysis of sulbactam against Acinetobacter baumannii pneumonia: establishing in vivo efficacy targets in the epithelial lining fluid.

Abouelhassan Y, Kuti JL, Nicolau DP, Abdelraouf K. Abouelhassan Y, et al. Among authors: nicolau dp. JAC Antimicrob Resist. 2024 Dec 20;6(6):dlae203. doi: 10.1093/jacamr/dlae203. eCollection 2024 Dec. JAC Antimicrob Resist. 2024. PMID: 39712636 Free PMC article.

7

Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model.

Fratoni AJ, Padgett AM, Roenfanz HF, Duffy EM, Nicolau DP. Fratoni AJ, et al. Among authors: nicolau dp. J Antimicrob Chemother. 2024 Dec 5:dkae432. doi: 10.1093/jac/dkae432. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39657022

8

Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis.

Koenig C, Monogue ML, Shields RK, Sakon CM, Fratoni AJ, Roenfanz HF, Finklea JD, Pope JS, Nicolau DP, Kuti JL. Koenig C, et al. Among authors: nicolau dp. Antimicrob Agents Chemother. 2024 Dec 10:e0153924. doi: 10.1128/aac.01539-24. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 39655913 Free article.

9

Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations.

Abouelhassan Y, Shen Y, Chen A, Ye X, Nicolau DP, Kuti JL. Abouelhassan Y, et al. Among authors: nicolau dp. Antimicrob Agents Chemother. 2024 Dec 10:e0167423. doi: 10.1128/aac.01674-23. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 39655912 Free article.

10

Dose optimization of piperacillin/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in Türkiye.

Buyukyanbolu E, Gill CM, Genc L, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP. Buyukyanbolu E, et al. Among authors: nicolau dp. Eur J Clin Microbiol Infect Dis. 2025 Jan;44(1):159-165. doi: 10.1007/s10096-024-04990-w. Epub 2024 Nov 15. Eur J Clin Microbiol Infect Dis. 2025. PMID: 39546100

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

877 results

Search Page

Filters